Therefore, the inclusion of ccCK18 in a biomarker panel (cancer antigen 125, human epididymis protein 4, e-cadherin,...)83–85 in ovarian cancer therapy should not be neglected. This evidence concerns the gene MUC16 and ovarian cancer.